The shareholders of TAP Biosystems Group have approved Sartorius Stedim Biotech’s takeover offer valued at approximately $44 million. The transaction is expected to close at the end of the year.
The acquisition expands Sartorius’ bioprocess portfolio in the area of fermentation, particularly in the early phases of product and process development. TAP Biosystems, headquartered in Royston, UK, specializes in the design and development of small scale, multi-parallel fermentation and cell culture systems for biopharmaceutical applications. TAPs’ portfolio includes automated cell processing systems and other benchtop equipment. TAP Biosystems generated sales revenue of approximately $35 million in 2012-13 and has approximately 160 employees worldwide.